Year-end Sale % OFF 
Abstract
Objective: Bevacizumab has activity in ovarian cancer (OC). Docetaxel is an active chemotherapeutic in recurrent OC and the combination with bevacizumab appears to be tolerable and efficacious in other cancers. We therefore studied the efficacy and tolerability of combination docetaxel and bevacizumab in patients with recurrence of OC within one year of platinum-based therapy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
